We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Life Sciences

  • October 18, 2018

    Casino Biz Prices $359M IPO, Biotech Firms Fall Short

    Macau-based casino company Studio City International Holdings Ltd. began trading on the New York Stock Exchange on Thursday after cashing in on a $359 million initial public offering, while a pair of biotechnology firms priced their offerings below their original targets.

  • October 18, 2018

    Miramar Finalizes Settlement Over Sientra Merger Suit

    Shareholders of medical technology firm Miramar Labs Inc. and eight of the company’s shareholders filed a stipulation of settlement Thursday in Delaware Chancery Court that calls for $118,500 in plaintiff attorneys' fees and expenses in a $410,000 settlement that seeks to bring an end to the investors’ suit over a $20 million merger with Sientra Inc. in 2017.

  • October 18, 2018

    McMillan Steers IAnthus, MPX In $683M Cannabis Co. Merger

    MPX Bioceutical Corp. and iAnthus Capital Holdings Inc. said Thursday they have agreed to the terms of a merger that will see the cannabis firms combine in an all-stock transaction with an offered equity consideration to MPX shareholders valued at CA$835 million ($638.3 million), a deal guided by McMillan LLP.

  • October 18, 2018

    Jury Told Of Seized Drugs, Unsafe Workplace At NECC Trial

    A prosecutor wearing purple protective gloves in Massachusetts federal court on Thursday presented a series of apparently expired drugs seized from the New England Compounding Center in 2012 as the government tried to build its case that the facility's operations were sloppy and unsafe before a deadly meningitis outbreak that killed dozens of people.

  • October 18, 2018

    LabMD Exec Sees FCA Suit Against Tiversa Trimmed

    A New York federal judge has trimmed a False Claims Act suit brought by the president of LabMD accusing cybersecurity firm Tiversa of fabricating data breaches to secure government contracts, concluding that the executive sufficiently alleged fraud for some claims, but that others don’t hold up.

  • October 18, 2018

    Horizon Wants DLA Piper DQ'd In Hemophilia Treatment Row

    Horizon Healthcare Services Inc. has sought to disqualify DLA Piper LLP from representing a group of specialty pharmaceutical companies who sued Horizon for allegedly refusing to pay for health plan members' hemophilia treatments, arguing that the law firm was still representing Horizon when it decided to take the case.

  • October 18, 2018

    Glenmark Moves To Ax Zetia Pay-For-Delay Claims

    Glenmark Pharmaceuticals Inc. has asked a Virginia federal judge to nix a suit accusing it of conspiring with Merck & Co. to delay production of a competitor to Merck's cholesterol treatment Zetia, saying that a private settlement with Merck did not prevent the launch of lower-priced alternatives.

  • October 18, 2018

    Amgen Makes £50M Investment In Genetic Sequencing Co.

    Amgen Inc. is making a £50 million ($66 million) equity investment in U.K.-based Oxford Nanopore Technologies Ltd., which develops gene sequencing technology for its handheld and laboratory-grade devices, the companies said Thursday.

  • October 18, 2018

    Cravath, Faegre Steer Novartis' $2.1B Deal For Endocyte

    Novartis AG said Thursday it will take over cancer therapy firm Endocyte Inc. in a $2.1 billion deal, with Cravath Swaine & Moore LLP guiding the Swiss pharmaceutical giant and Faegre Baker Daniels LLP steering the U.S.-based biopharmaceutical company.

  • October 17, 2018

    Aceto Execs Hit With Derivative Suit Over Stock Drop

    A shareholder of pharmaceutical manufacturer Aceto Corp. filed a derivative suit in New York federal court Wednesday accusing company executives of misleading investors by failing to disclose an impending financial loss despite guidance in early 2018 predicting the opposite.

  • October 17, 2018

    FTC On Ropes As Courts Wallop Suits Over Past Conduct

    The Federal Trade Commission's power to punish past conduct involving consumer fraud or anti-competitive shenanigans is looking wobbly after a one-two punch of court decisions forcing the agency to also identify imminent or ongoing violations when it challenges prior behavior.

  • October 17, 2018

    A High Court Milestone Stirs Hope Of Gender Parity

    After an emotionally fraught confirmation process with sexual misconduct allegations front and center, a new justice joins the Supreme Court bench and brings four female clerks with him. The hires bring gender parity to the court's clerkship ranks for the first time, but will the shift be long-lasting?

  • October 17, 2018

    Cooley-Led Med Device Co. Prices $108M IPO Amid Volatility

    Medical device company Si-Bone Inc., advised by Cooley LLP, priced a $108 million initial public offering and saw shares rally upon debut on Wednesday amid volatile market conditions during which at least one other company has delayed its IPO and another lowered its price.

  • October 17, 2018

    J&J Wants $20M Pa. Mesh Award Axed Over Alleged Time Bar

    A $20.2 million verdict against a Johnson & Johnson unit in a pelvic mesh injury case came under fire on Wednesday as a Pennsylvania appeals court heard arguments that the lawsuit that led to the award had been filed outside of the two-year statute of limitations.

  • October 17, 2018

    20 Drugmakers Must Face Generic Price-Fixing MDL

    A Pennsylvania federal court has greenlighted the first round of multidistrict litigation accusing more than 20 generic-drug makers of conspiring to fix their prices, excusing only Teligent Inc. from the antitrust litigation.

  • October 17, 2018

    Bayer Cholesterol Drug FCA Suit Survives Dismissal Bid

    A Minnesota federal court judge has kept alive a long-running False Claims Act suit alleging that Bayer AG misled the U.S. Department of Defense about the risks of its now-defunct cholesterol drug Baycol, finding that the relator had presented enough evidence to show that she had direct knowledge of the alleged fraud.

  • October 17, 2018

    2 Biotech Cos. Launch IPOs Despite Erratic Market Conditions

    Two biotechnology companies on Wednesday set price ranges on initial public offerings that are expected to raise $125 million combined, opting to move forward on IPOs in a stock market that has swung sharply in the past week.

  • October 17, 2018

    Calif. Tribes Become Latest To Bring Opioid Crisis Suits

    Two Native American tribes from California added to the flood of litigation stemming from the prescription opioid crisis with a pair of Ohio federal court suits alleging that their communities have been disproportionately devastated by the epidemic fueled by drug manufacturers and distributors.

  • October 17, 2018

    Imerys Fights Jurisdictional Ruling In NJ Asbestos Talc Row

    Imerys Talc America Inc. cannot be held liable over claims a woman developed mesothelioma from her alleged exposure to asbestos in talc supplied by another entity that was later connected to an Imerys predecessor, a company attorney told a New Jersey state appellate panel Wednesday in its bid to exit the litigation.

  • October 17, 2018

    Lens Makers Look To Nix Price-Fixing Claims From MDL

    Several major contact lens manufacturers urged a Florida federal judge on Tuesday to slice two types of antitrust claims off sprawling multidistrict litigation accusing them of conspiring to keep prices high, calling the consumers' arguments fatally flawed.

Expert Analysis

  • Q&A

    Back To School: BC's Kent Greenfield Talks Corporate Law

    Kent Greenfield

    In this series featuring law school luminaries, Boston College Law School professor Kent Greenfield reflects on his corporate law theories, his legal battle with the Pentagon over free speech and gay rights, and important constitutional law issues to watch out for.

  • The Rise In ESG Investing — And What Boards Can Do

    Peter Atkins

    Public companies are being bombarded with messages, requests and demands around environmental, social and governance matters. At least for companies incorporated in states such as Delaware, directors should consider whether there is a nexus between ESG issues and the pursuit of shareholder welfare, say attorneys with Skadden Arps Slate Meagher & Flom LLP.

  • Kavanaugh Cannot Be Compelled To Recuse Himself

    Donald Scarinci

    Whether Justice Brett Kavanaugh’s prior statements may be grounds for disqualification when it comes to judging certain cases is debatable, but there are no specific recusal guidelines for the U.S. Supreme Court. The justices themselves don’t even agree on where to draw the line when it comes to perceived political bias, says Donald Scarinci, a founding partner of Scarinci Hollenbeck LLC.

  • Opinion

    Gov't Brief In Fosamax Makes Strong Case For Reversal

    Stephen McConnell

    After agreeing to review the Third Circuit's 2016 ruling in the Fosamax product liability litigation during the current term, the U.S. Supreme Court invited the federal government to file an amicus brief. A review of the compelling arguments laid out in the brief strongly suggests that this problematic decision will be reversed by the high court, says Stephen McConnell of Reed Smith LLP.

  • Knowledge Management: An Unsung Hero Of Legal Innovation

    Rob MacAdam

    As technology evolves, law firms are increasingly looking for ways to improve communication, transparency and service for their clients. Firms should put knowledge management at the core of their value proposition to create a competitive advantage, says Rob MacAdam at HighQ.

  • What New Calif. Law Means For Connected Medical Devices

    Michael Buchanan

    Last month, California passed the first-ever state legislation aimed at regulating "internet of things" devices. The new law restricts liability to manufacturers of physical hardware — drawing a narrower line than the U.S. Food and Drug Administration's previous guidance, say Michael Buchanan and Michelle Bufano of Patterson Belknap Webb & Tyler LLP.

  • Akorn Could Alter 'Material Adverse Effect' Law In Delaware

    J.B. Heaton

    The Delaware Chancery Court's opinion this week in the Fresenius-Akorn merger dispute will likely be appealed. That appeal will determine whether this case is destined to change the understanding of material adverse effect, or whether the Chancery Court overreached on the law and the facts, says J.B. Heaton of the University of Chicago Law School.

  • Opinion

    Skip The New 'Civility Courses' And Think Like A Lawyer

    Alex Dimitrief

    As we watch what passes for political discourse in our nation’s capital, it’s understandable that universities are launching programs on how to cope with ideological disputes. But our country needs fewer people who profess to be open-minded and more people who engage in and honor the conclusions of reasoned debates, says Alex Dimitrief of General Electric Co.

  • Why Law Firms Should Monitor The Dark Web

    Anju Chopra

    Dark web monitoring allows law firms to see what sensitive information may have made its way onto the thriving global underground marketplace where cybercriminals buy and sell exposed data. It can also help lawyers advise clients on a wide range of legal and business matters, say Anju Chopra and Brian Lapidus of Kroll.

  • Does Rule 45 Protect Nonparties From Undue Burden?

    Matthew Hamilton

    Interpretations of Rule 45 protections vary but what's clear is that "undue burden" does not mean no burden at all. To avoid the costs of compliance with a subpoena, a nonparty should be ready to demonstrate its disinterest in the litigation and the anticipated cost and burden of compliance, say attorneys at Pepper Hamilton LLP.